SAB Biotherapeutics announced that the Navy Medical Research Command is moving forward with a safety and tolerability study to evaluate SAB-176, a therapy being investigated for use as a pre- and post-exposure prophylactic treatment for influenza type A and type B, pursuant to the Cooperative Research and Development Agreement that governs the relationship between SAB and the NMRC. With funding for research provided by the Henry Jackson Foundation, this partnership will move forward a pharmacokinetic , safety and tolerability study designed as a double-blinded, randomized study with intramuscular SAB-176 administered to healthy volunteers. The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr. Nehkonti Adams, Director, NMRC Clinical Trials Center.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Secures Leadership with New Executive Contracts
- SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
- SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- SAB Biotherapeutics Announces New Appointment Update
- SAB Biotherapeutics Names Samuel J. Reich as CEO